In MECP2 positive patients, epilepsy usually begins in stages II and III of the disease, between 7 and 12 years of age and an early onset seems to be associated with a worsening evolution toward forms that are poorly responsive to therapy, epileptic state. Here, MECP2 is linked to epilepsy.